



IPSOGEN
CANCER PROFILER

PRESS RELEASE

IPSOGEN TO HOLD ORDINARY AND EXTRAORDINARY GENERAL MEETINGS OF SHAREHOLDERS ON NOVEMBER 14, 2012, IN PARIS, FRANCE

Marseille, France, October 22, 2012 - IPSOGEN (Alternext - FR0010626028 - ALIPS), will hold General Meetings of Shareholders on November 14, 2012, at 2:00 pm in Darrois Villey Maillot Brochier offices, 69 avenue Victor Hugo, 75116 Paris.

The Notice of Meeting of these ordinary and extraordinary General Meetings of Shareholders was published on October 10, 2012 in the French official legal bulletin ("BALO").

At these General Meetings of Shareholders, important measures will be submitted to the approval of shareholders. Foremost among these measures, the integration of distribution networks of IPSOGEN and QIAGEN. The Company believes that it will benefit from the strong position of the QIAGEN Group on the market in human health diagnostics and its global sales network. The implementation of this system of distribution requires the conclusion of a global "Distribution Agreement", excluding Japan, between the Company and the QIAGEN Group, which should take effect on January 1, 2013.

All the documentation regarding these General Meetings of Shareholders is made available to shareholders in accordance with existing regulations and on the Company's website: <http://www.ipsogen.com/en/investorroom/documentation-center/general-meeting-of-shareholders-documents>.

PRECISION REGARDING THE ORDINARY AND EXTRAORDINARY GENERAL MEETINGS OF SHAREHOLDERS:

Only shareholders having registered their shares at least three business days prior to the date of the General Meetings of Shareholders, by midnight Paris time, will be able to attend.

Shareholders holding "au porteur" (bearer) shares will need to obtain an "attestation de participation" (certificate of shareholding) from their brokers. This "attestation de participation" must be attached to the proxy form or to the appropriate voting form if shareholders wish to designate a proxy or vote by mail. The "attestation de participation" may replace the admission card for shareholders wishing to attend the General Meetings of Shareholders in person.

Written questions from shareholders must be received from the day of the publication of the official Notice of Meeting of the General Meetings of Shareholders up until four business days prior to the General Meetings of Shareholders:

- by registered letter, addressed to IPSOGEN, Relations investisseurs, Luminy Biotech Entreprises, Case 923, 163 avenue de Luminy, 13288 Marseille Cedex 9, France or
- by e-mail to investisseurs@ipsogen.com

Shareholders may obtain the legal documentation in preparation of the General Meetings of Shareholders (as described in article R. 225-83 of the French "Code de Commerce") by sending a request by regular mail or e-mail to the above mentioned addresses.



IPSOGEN
CANCER PROFILER

PRESS RELEASE

About IPSOGEN

IPSOGEN, "Cancer Profiler," develops and markets molecular diagnostic tests designed to map diseases in order to guide patients and oncologists' decisions along their complex therapeutic path.

With more than 80 tests already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with blood cancer, IPSOGEN is also targeting breast cancer. Its goal will be to provide diagnostic information that remained unavailable until now.

IPSOGEN is, since July 2011, a subsidiary of the QIAGEN group.

At end of June 2012, IPSOGEN employs 76 persons. It is headquartered in Marseille, France.

For further information, visit www.ipsogen.com.

Contacts

IPSOGEN

Vincent Fert

CEO

Tel: + 33 (0)4 9129 3090

fert@ipsogen.com

ATCG Press

Communication

& Press relations

Marielle Bricman

Tel : + 33 (0)6 26 94 18 53

ipsogen@atcg-partners.com

ALIPS
LISTED
NYSE
ALTERNEXT